Eric Hoffman

Biography

Dr. Hoffman has worked on DMD since the late 1980’s, first working as a post-doctoral fellow with Louis Kunkel at Boston Children’s to identify the gene and protein (1986-1990), then running his own research group at University of Pittsburgh (1990-1998), then Children’s National Medical Center in Washington DC (1998-present). He has led development of molecular diagnostics in muscular dystrophies, as well as efforts to understand the function of dystrophin in normal muscle, and the consequences of its absence in DMD. He co-founded ReveraGen in 2008 together with Drs. McCall and Nagaraju, and was appointed as CEO in 2014. Dr. Hoffman splits his time between his position as Associate Dean for Research in the School of Pharmacy and Pharmaceutical Sciences at Binghamton University and guiding ReveraGen as CEO. 

Research Interest

His research interests were gene and protein at Boston Children's and ReveraGen Biopharma is involved in transforming academic medicine into innovative therapies through partnerships and Innovations in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models for orphan drug development. IP licensed to ReveraGen Biopharma on the topic "microRNAs shown to define dystrophin levels in patient muscle"